Brussels, Belgium, 14 June, 2011 ï¿½ The Innovative Medicines Initiative (IMI) and the Critical Path Institute (C-Path) announced today that they have signed a Memorandum of Understanding (MoU) to further the missions of both organisations.
IMI, based in the European Union, and C-Path, based in the United States, share similar objectives that accelerate the development of safer, more effective medicines for patients. Both organisations bring together scientists from the pharmaceutical industry and academic institutions, as well as representatives from patient organisations, small and medium-sized enterprises and regulatory agencies, by forming precompetitive public-private partnerships. By combining their knowledge and expertise in innovative projects, the scientists in these partnerships are able to tackle challenges that are too big and complex for individual research teams to handle on their own. This MoU indicates the intent of IMI and C-Path to find opportunities to leverage one anotherï¿½s work in order to accelerate progress and prevent duplication of efforts.